Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review
The Journal of Infectious Diseases · 23.09.2024 · 230 (3) · e508-e517
DOI: 10.1093/infdis/jiae134 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.04.2024. Verfasst von Michael Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Westmead, NSW, Australia. Hauptthemen laut MEDLINE: Biofilms, Vaginosis, Bacterial, Anti-Bacterial Agents, Probiotics. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bacterial vaginosis (BV) is difficult to eradicate due to BV biofilms protecting BV bacteria (Gardnerella, Prevotella, and other genera). With the growing understanding of biofilms, we systematically reviewed the current knowledge on the efficacy of anti-BV biofilm agents.
Methods
We searched literature in the Scopus, Medline, and Embase databases for empirical studies investigating substances for the treatment of BV biofilms or prevention of their recurrence and their efficacy and/or safety.
Results
Of 201 unique titles, 35 satisfied the inclusion criteria. Most studies (89%) reported on preclinical laboratory research on the efficacy of experimental antibiofilm agents (80%) rather than their safety. Over 50% were published within the past 5 years. Agents were classified into 7 groups: antibiotics, antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants/surfactant components. Enzymes and probiotics were most commonly investigated. Earlier reports of antibiotics having anti-BV biofilm activity have not been confirmed. Some compounds from other classes demonstrated promising anti-BV biofilm efficacy in early studies.
Conclusions
Further research is anticipated on successful antibiofilm agents. If confirmed as effective and safe in human clinical trials, they may offer a breakthrough in BV treatment. With rising antibiotic resistance, antibiofilm agents will significantly improve the current standard of care for BV management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Westmead, NSW, Australia.
- Faculty of Medicine and Health, Westmead Clinical School, Westmead, NSW, Australia.
- Infection Immunity and Inflammation, Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Westmead, NSW, Australia.
- Sydney Institute of Infectious Diseases, The University of Sydney, Westmead, NSW Australia.
- School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
- Whiteley Corporation, North Sydney, NSW, Australia.
ORCID-Profile: Michael Gao, Iryna Zablotska-Manos
Zitieren
APA
Gao, M., Manos, J., Whiteley, G., & Zablotska-Manos, I. (2024). Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review. The Journal of Infectious Diseases, 230(3), e508-e517. https://doi.org/10.1093/infdis/jiae134
Vancouver
Gao M, Manos J, Whiteley G, Zablotska-Manos I. Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review. The Journal of Infectious Diseases. 2024;230(3):e508-e517. doi:10.1093/infdis/jiae134
BibTeX
@article{Gao2024,
author = {Gao, Michael and Manos, Jim and Whiteley, Greg and Zablotska-Manos, Iryna},
title = {Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {3},
pages = {e508--e517},
doi = {10.1093/infdis/jiae134}
}
EUVIMED